Scalper1 News
Incyte (INCY) stock hit a 15-year high Friday after the release of new clinical-trial data on the biotech’s cancer drug epacadostat, following a fresh round of buyout speculation this week. A release of abstracts for presentations at the European Society for Medical Oncology (ESMO) assembly next weekend included Incyte’s trial of epacadostat in combination with Bristol-Myers Squibb’s (BMY) Yervoy to treat melanoma. Though it was a small study with Scalper1 News
Scalper1 News